Unlock Faster Drug Absorption: The Mini-Ussing Chamber Revolution
"Simultaneous prediction of intestinal absorption and metabolism with a new approach for better drug development."
Oral bioavailability is key to successful drug development, depending on factors such as intestinal cell permeability (Fa), gut metabolism (Fg), and liver metabolism (Fh). A drug's ability to be absorbed is generally impacted by its physicochemical properties, including molecular weight, lipophilicity, and solubility, as well as intestinal enzymes and transporters.
Enzymes and transporters, such as CYP3A4 and P-gp, are known to lower Fa × Fg in humans. The differentiation of Fa from Fa × Fg is critical for identifying appropriate clinical candidates from a human oral absorbability standpoint. Caco-2 cell monolayers, transfected cell lines, and subcellular fractions of the intestinal epithelium are effective in vitro models for understanding intestinal disposition processes like uptake, transporter-mediated transport, and metabolism.
The goal of this research was to use the transport index (TI) of midazolam (a BCS class 1 compound) and nifedipine (a BCS class II compound) in the presence and absence of ketoconazole (a CYP3A inhibitor) to assess the effect of intestinal metabolism on Fa x Fg quantitatively.
Limits of Conventional Absorption Models
The oral route is the most common and practical means of drug administration, particularly from a patient’s perspective. Oral pharmacokinetics depends on the rate of drug absorption through the intestinal wall before the drug reaches systemic circulation. Reviews note that many in vitro models fail to reproduce key features of the human small-intestinal epithelium and have limited ability to predict drug absorption and metabolism during preclinical development. The small intestine can also contribute to first-pass metabolism through gastrointestinal drug-metabolizing enzymes, potentially limiting bioavailability despite complete absorption.
From Permeability to Transporters
The extent of absorption after oral administration is influenced by intestinal membrane permeability and metabolism, as well as hepatic metabolism. The introduction of molecular biological techniques enabled the identification of drug transporters responsible for intestinal absorption of a wide variety of drugs. Each transporter has its own substrate specificity, although transporters commonly recognize broad groups of substrates. These developments supported high-throughput in vitro systems for assessing intestinal absorption, metabolism, excretion, and potential drug-drug interactions.
What is the Mini-Ussing Chamber System?
The Ussing chamber system is a powerful experimental setup used to simultaneously measure membrane permeability and enzyme/transporter interactions. It can also be used with human intestinal tissues. We previously introduced the transport index (TI) value, which can correctly predict human Fa by using small intestinal tissues from dogs and rats in mini-Ussing chambers, and showed a strong correlation with human data. This system has the advantage of accounting for changes in drug solubility during incubations as well as drug accumulation in tissues.
- Animal Intestinal Tissues: Rat jejunum tissues were taken from male Sprague-Dawley (SD) rats with ethical approval and were immediately placed in ice-cold transport buffer.
- Transport Experiment in Mini-Ussing Chamber: Mini-Ussing chambers were prepared as previously reported. Intestinal tissues were mounted vertically in the chambers after removing the muscle layer. The available permeation area was 0.20 cm², and the solution temperature was kept at 37°C.
- Calculation of Transport Index: TI values were used to measure permeability based on the actual drug concentration in the apical compartment of the mini-Ussing chamber system. TI value was defined as the sum of the percent of the dose transported and tissue-accumulated.
Mini-Ussing Chambers in Current Research
Recent research has examined the Mini-Ussing Chamber System for simultaneous prediction of intestinal absorption and metabolism. One reported approach uses a metabolites formation index, defined from the percentage of the dose represented by produced metabolites and corrected using the area under the curve of the parent drug in the apical compartment. Another study evaluated the permeability of 22 drugs in rat intestines with a Ussing chamber and compared the results with reported Caco-2 permeability data. Recent reviews also emphasize that gut microbiota can influence drug metabolism, absorption, and pharmacokinetics.
Ketoconazole Formulation Example
A source discussing ketoconazole in seborrheic dermatitis reports the launch of an anhydrous gel containing ketoconazole 2%. It states that the formulation’s ancillary properties were optimized. This example illustrates how formulation design can be considered alongside the active ingredient when evaluating a drug product. The source does not provide a Mini-Ussing Chamber comparison or absorption data for the formulation.
Future Implications for Drug Development
The mini-Ussing chamber system can simultaneously predict intestinal absorption and metabolism. Expanding the exposed tissue area improved intestinal metabolism activities. Further studies using P450/P-gp substrates could clarify P-gp's contribution to Fa × Fg, leading to a better understanding of metabolic enzymes and efflux transporters.
Connecting Gut Processes to Human Pharmacokinetics
Quantifying the multiple processes that control and modify oral bioavailability is critical for accurately projecting human pharmacokinetics. Gut wall metabolism and hepatic elimination are important parts of this assessment. Expert commentary in drug metabolism and toxicology provides a forum for discussing emerging research approaches in ADME-Tox, along with metabolic, pharmacokinetic, and toxicological issues involving drugs, drug-drug interactions, and drug classes. Together, these sources place intestinal absorption within the broader analysis of drug disposition.
Targeting Absorption Across the Gut
Future approaches to oral drug delivery must account for distinct target regions of the gastrointestinal tract, including the stomach, small intestine, and colon. A 2024 review identifies cellular permeability, digestive enzymes, and variations in luminal pH as physiological barriers that affect drug absorption. These barriers help define where and how delivery strategies may be designed. Regional targeting is therefore presented as a way to address physiological conditions that influence absorption.
The Systemic Complexity of Oral Delivery
The oral route is the most common and practical means of drug administration, particularly from the patient’s perspective. However, the pharmacokinetic profile of an oral drug depends on the rate at which it is absorbed through the intestinal wall before entering systemic circulation. This makes intestinal absorption a central determinant of oral drug performance. The cited 2022 source frames these absorption challenges as part of efforts to improve oral drug delivery.